Xuefeng YU, PhD
Co-Founder/Chief Executive Officer/Chairman

Xuefeng YU, co-founder, Chief Executive Officer(CEO) and Chairman of CanSino Biologics. He is primarily responsible for overseeing strategic development, overall operations and management as well as being the major decision-making force of our company. In addition, Dr. Yu is also responsible for managing our commercial operations center. He has more than 30 years' experience in biotech research and development. From September 1990 to June 1991, Dr. Yu worked as a lecturer in the Biology Department at Nankai University. From 1996 to 1998, he served as staff scientist at IBEX Technologies, Inc. (a company listed on the Toronto Stock Exchange Venture Exchange, ticker symbol: IBT). Dr. Yu joined Sanofi Pasteur in May 1998 and held the position of director of fermentation development in Canada when he left the company in August 2009.

read more retract
Shoubai CHAO, PhD
Chief Operating Officer/Executive Director

Shoubai CHAO, Chief Operating Officer(COO) and Executive Director of CanSino Biologics. He is deputy general manager of our company and is primarily responsible for the management of daily operations and strategy development. In addition, Dr. Chao also oversees production management and quality control. With nearly 33 years' experience in the biotechnology industry, he formerly served as Vice President and Senior Vice President at AstraZeneca plc from January 2008 to April 2018, and was president and the Board Director at the Chinese Biopharmaceutical Association-USA from June 2014 to June 2016.

read more retract
Tao ZHU, PhD
Co-Founder/Chief Scientific Officer

Tao ZHU, co-founder, Chief Scientific Officer(CSO) and Executive Director of CanSino Biologics. He is primarily responsible for leading  vaccine research and development for CanSinoBIO. In addition, Dr. Zhu also oversees  the management of regulatory and clinical affairs. Together with experts from the  Academy of Military Medical Sciences, Dr. Zhu led the development and pre-clinical research of the only available recombinant ebola vaccine in China, the production of which was approved by the CFDA. He also led the combinational vaccine project and PBPV project, both of which have been selected as one of the major science and technology projects in the National Twelfth Five-Year Plan for “Significant New Drug Creation” . His achievements also include the establishment of a conjugation technology platform and the development of a variety of vectors including CRM197, plus the process development, pre-clinical research and clinical application of several products, including MCV4, and the invention of seven patents in the PRC.

read more retract
Dongxu QIU, PhD
Co-Founder/Executive Vice President

Dongxu QIU, co-founder, Executive Vice President and Executive Director of CanSino Biologics.He is primarily responsible for advising on the business and strategic development of our company. Dr. Qiu has around 25 years' experience in the biotechnology industry. Dr. Qiu has led several rounds of corporate financing as well as the technology transfers . From January 1993 to April 1997, he was a research scientist at Biomira. Inc. From 1999 to 2000, he served as associate director of product operations at Altarex Inc., responsible for analytical development and product formulation. Dr. Qiu  became head of scientific operations at ARIUS Research Inc. from 2000 to 2002, president of Asia at MDS Capital from May 2003 to September 2005, deputy general manager at Shanghai Jima Pharmaceutical Technology Co., Ltd. from 2006 to 2009, and general manager at ChinaBio LLC from March 2007 to April 2011.

read more retract
Chief Commercial Officer/Executive Director

Jing WANG, Executive Director and Chief Commercial Officer of CanSino Biologics, is mainly responsible for the company's overall commercial operation. Ms. Wang holds a bachelor degree in Economics, a master degree in engineering of Peking University and Global EMBA of CEIBS. After joining the Company in June 2012, Ms. Wang has made outstanding achievements in previous positions such as director of personnel,administration department, operation director, financial director and assistant to the chairman. Ms. Wang has led the establishment of our financing, financial operations, human resource and administration systems as well as completing the pre-IPO fundraising of approximately RMB743 million. Ms. Wang successfully led the Company’s IPO on Main Board of Hong Kong Stock Exchange in 2019 and on the Sci-tech Innovation Board of the Shanghai Stock Exchange in August 2020, making the Company the first “A+H” dual listing vaccine company.

read more retract